FI944676A0 - Rokotteita, jotka sisältävät ionisoitumattomia pinta-aktiivisten aineiden vesikkeleitä - Google Patents

Rokotteita, jotka sisältävät ionisoitumattomia pinta-aktiivisten aineiden vesikkeleitä

Info

Publication number
FI944676A0
FI944676A0 FI944676A FI944676A FI944676A0 FI 944676 A0 FI944676 A0 FI 944676A0 FI 944676 A FI944676 A FI 944676A FI 944676 A FI944676 A FI 944676A FI 944676 A0 FI944676 A0 FI 944676A0
Authority
FI
Finland
Prior art keywords
pct
vesicles
ionic surfactant
sec
containing non
Prior art date
Application number
FI944676A
Other languages
English (en)
Swedish (sv)
Other versions
FI944676A (fi
Inventor
James Alexander
Brewer James Macdonald
Original Assignee
Proteus Molecular Design
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteus Molecular Design filed Critical Proteus Molecular Design
Publication of FI944676A0 publication Critical patent/FI944676A0/fi
Publication of FI944676A publication Critical patent/FI944676A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/45—Toxoplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Dispersion Chemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
FI944676A 1992-04-07 1994-10-06 Rokotteita, jotka sisältävät ionisoitumattomia pinta-aktiivisten aineiden vesikkeleitä FI944676A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929207731A GB9207731D0 (en) 1992-04-07 1992-04-07 Improvements in or relating to vaccines
PCT/GB1993/000716 WO1993019781A1 (en) 1992-04-07 1993-04-06 Vaccines containing non-ionic surfactant vesicles

Publications (2)

Publication Number Publication Date
FI944676A0 true FI944676A0 (fi) 1994-10-06
FI944676A FI944676A (fi) 1994-10-06

Family

ID=10713695

Family Applications (1)

Application Number Title Priority Date Filing Date
FI944676A FI944676A (fi) 1992-04-07 1994-10-06 Rokotteita, jotka sisältävät ionisoitumattomia pinta-aktiivisten aineiden vesikkeleitä

Country Status (16)

Country Link
US (1) US5679355A (fi)
EP (1) EP0634937B1 (fi)
JP (1) JP2690620B2 (fi)
KR (1) KR950700758A (fi)
CN (1) CN1085449A (fi)
AT (1) ATE158185T1 (fi)
AU (1) AU3899793A (fi)
CA (1) CA2132547C (fi)
DE (1) DE69314020T2 (fi)
FI (1) FI944676A (fi)
GB (1) GB9207731D0 (fi)
HU (1) HUT69935A (fi)
NO (1) NO943739L (fi)
NZ (1) NZ251402A (fi)
WO (1) WO1993019781A1 (fi)
ZA (1) ZA932491B (fi)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003035A1 (en) * 1993-07-23 1995-02-02 Massachusetts Institute Of Technology Polymerized liposomes with enhanced stability for oral delivery
US5919466A (en) * 1993-10-01 1999-07-06 Gerbu Biotechnik Gmbh Method for improving the yield of immunoantibodies in the vaccination of animals and humans
GB9320597D0 (en) * 1993-10-06 1993-11-24 Proteus Molecular Design Improvements in and realting to vaccines
AU680996B2 (en) * 1993-12-17 1997-08-14 Novavax, Inc. Method of transmitting a biologically active material to a cell
US5688506A (en) * 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
GB9515868D0 (en) * 1995-08-02 1995-10-04 Proteus Molecular Design Therapeutic method
GB9600471D0 (en) * 1996-01-10 1996-03-13 Univ London Pharmacy Drug delivery system
CA2325939A1 (en) * 1998-04-09 1999-10-21 Martin Friede Vaccine
US6494865B1 (en) * 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
FR2802422B1 (fr) * 1999-12-21 2002-08-09 Capsulis Structures mixtes resultant de l'incorporation d'une macromolecule biologique, en particulier d'adn, dans une phase structuree d'amphiphiles et vesicules obtenues a partir de ces structures
GB9930591D0 (en) * 1999-12-23 2000-02-16 Univ London Component for vaccine
FI112825B (fi) * 2001-07-11 2004-01-15 Antti Nissinen Menetelmä alkoholinkulutuksen osoittamiseksi, menetelmässä käytettäviä välineitä sekä niiden valmistus
AU2003267984A1 (en) * 2002-07-03 2004-01-23 Receptor Biologix, Inc. Liposomal vaccine
CN1711074B (zh) * 2002-11-15 2010-10-06 尼普洛株式会社 脂质体
FR2850872A1 (fr) * 2003-02-12 2004-08-13 Ethypharm Sa Composition vaccinale destinee a induire une reponse immunitaire contre le virus responsable du sida
WO2005025641A2 (en) 2003-08-28 2005-03-24 Becton, Dickinson And Company Intradermal injection device
US8202523B2 (en) * 2005-09-22 2012-06-19 ProSci, Inc. Glycosylated polypeptides produced in yeast mutants and methods of use thereof
KR101701198B1 (ko) 2008-06-19 2017-02-01 배리에이션 바이오테크놀로지스 아이엔씨. 인플루엔자를 치료하기 위한 조성물 및 방법
US8788042B2 (en) 2008-07-30 2014-07-22 Ecole Polytechnique Federale De Lausanne (Epfl) Apparatus and method for optimized stimulation of a neurological target
EP2604313B1 (en) 2008-11-12 2014-09-17 Ecole Polytechnique Federale de Lausanne Microfabricated neurostimulation device
WO2011005772A1 (en) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
AU2010270722B2 (en) 2009-07-06 2015-06-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
JP2013512062A (ja) 2009-12-01 2013-04-11 エコーレ ポリテクニーク フェデラーレ デ ローザンヌ 微細加工表面神経刺激デバイスならびにそれを作製および使用する方法
CA2795159C (en) 2010-04-01 2020-11-03 Ecole Polytechnique Federale De Lausanne Device for interacting with neurological tissue and methods of making and using the same
US9238796B2 (en) 2010-06-04 2016-01-19 Toagosei Co. Ltd. Cell growth-promoting peptide and use thereof
US9610248B2 (en) 2010-07-06 2017-04-04 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
CN103492415B (zh) * 2011-01-07 2017-12-29 精工爱普生株式会社 针对淀粉状蛋白前体蛋白质的信号肽的抗体
WO2012093706A1 (ja) * 2011-01-07 2012-07-12 東亞合成株式会社 抗疎水性ペプチド抗体を得るための抗原調製方法
CN103501811B (zh) 2011-01-13 2016-03-30 变异生物技术公司 用于治疗病毒感染的组合物和方法
EP2663288B1 (en) * 2011-01-13 2022-12-21 Variation Biotechnologies Inc. Methods for preparing vesicles and formulations produced therefrom
CN104302323A (zh) 2012-01-12 2015-01-21 变异生物技术公司 用于治疗病毒感染的组合物和方法
US20150079077A1 (en) 2012-01-27 2015-03-19 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
WO2013180011A1 (ja) 2012-05-28 2013-12-05 東亞合成株式会社 抗菌ペプチド及びその利用
US9480727B2 (en) 2012-10-18 2016-11-01 Toagosei Co. Ltd. Synthetic peptide for inhibiting expression of type 2 TNF receptor and use thereof
US11311718B2 (en) 2014-05-16 2022-04-26 Aleva Neurotherapeutics Sa Device for interacting with neurological tissue and methods of making and using the same
CN110585588A (zh) 2014-05-16 2019-12-20 阿莱瓦神经治疗股份有限公司 可植入式微电极装置
US9474894B2 (en) 2014-08-27 2016-10-25 Aleva Neurotherapeutics Deep brain stimulation lead
US9403011B2 (en) 2014-08-27 2016-08-02 Aleva Neurotherapeutics Leadless neurostimulator
CN109069824B (zh) 2016-02-02 2022-09-16 阿莱瓦神经治疗股份有限公司 使用深部脑刺激治疗自身免疫疾病
GB201612108D0 (en) * 2016-07-12 2016-08-24 Univ Strathclyde Preperation of non-ionic surfactant vesicles and variants
US10702692B2 (en) 2018-03-02 2020-07-07 Aleva Neurotherapeutics Neurostimulation device

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2408387A2 (fr) * 1975-06-30 1979-06-08 Oreal Compositions a base de dispersions aqueuses de spherules lipidiques
FR2571963B1 (fr) * 1984-10-24 1987-07-10 Oreal Composition a usage cosmetique ou pharmaceutique contenant des niosomes et au moins un polyamide hydrosoluble et procede de preparation de cette composition.
SE8405493D0 (sv) * 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
FR2597346B1 (fr) * 1986-04-22 1989-08-18 Oreal Procede pour faciliter la formation de niosomes en dispersion dans une phase aqueuse et pour ameliorer leur stabilite et leur taux d'encapsulation, et dispersions correspondantes.
JP2617346B2 (ja) * 1987-03-13 1997-06-04 マイクロ ベシキュラー システムズ，インコーポレイテッド 表面活性剤とステロイドから形成される脂質小胞
US4855090A (en) * 1987-03-13 1989-08-08 Micro-Pak, Inc. Method of producing high aqueous volume multilamellar vesicles
GB8713240D0 (en) * 1987-06-05 1987-07-08 Proteus Biotech Ltd Hormones
LU87449A1 (fr) * 1989-02-09 1990-09-19 Oreal Procede de fabrication de mousses utilisables dans les domaines cosmetique et pharmaceutique et mousses obtenues par ce procede
IT1238343B (it) * 1989-10-16 1993-07-13 Cesalpino Andrea Fond Procedimento per la preparazione di vaccini capaci di generare non solo la risposta immune dei linfociti t helper,ma anche un'efficace risposta di linfociti t citotossici,e vaccini con queste caratteristiche
CA2108039C (en) * 1991-03-28 2003-06-10 Elizabeth C. Albert Lipid vesicle containing water-in-oil emulsions

Also Published As

Publication number Publication date
AU3899793A (en) 1993-11-08
JP2690620B2 (ja) 1997-12-10
KR950700758A (ko) 1995-02-20
JPH07505389A (ja) 1995-06-15
NO943739D0 (no) 1994-10-05
ATE158185T1 (de) 1997-10-15
CN1085449A (zh) 1994-04-20
GB9207731D0 (en) 1992-05-27
CA2132547C (en) 2000-06-06
US5679355A (en) 1997-10-21
HUT69935A (en) 1995-09-28
ZA932491B (en) 1993-11-02
EP0634937A1 (en) 1995-01-25
DE69314020D1 (de) 1997-10-23
EP0634937B1 (en) 1997-09-17
HU9402904D0 (en) 1995-01-30
WO1993019781A1 (en) 1993-10-14
FI944676A (fi) 1994-10-06
NO943739L (no) 1994-10-05
DE69314020T2 (de) 1998-08-06
NZ251402A (en) 1996-10-28
CA2132547A1 (en) 1993-10-14

Similar Documents

Publication Publication Date Title
FI944676A0 (fi) Rokotteita, jotka sisältävät ionisoitumattomia pinta-aktiivisten aineiden vesikkeleitä
DK0705109T3 (da) Adjuvanser til vacciner mod respiratorisk syncytialvirus
AU4951196A (en) Vaccines for plague
DE60012711D1 (de) Adjuvanszusammensetzungen zur erhöhung der immunantwort auf polynukleotid-basierende impfstoffe
FR2814958B1 (fr) Composition vaccinale
HUP9801560A1 (hu) Szaponint és szterint tartalmazó vakcinák
ES2118963T3 (es) Vacunas combinadas, que contienen antigeno de superficie de la hepatitis b y otros antigenos.
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
DK0745387T3 (da) Adjuvanser til virale vacciner
ATE153071T1 (de) Neue proteinhaltige partikeln
IL130075A0 (en) A vaccine for eliciting an immune response to an antigen in an animal
DK1267924T3 (da) Immunterapeutiske metoder og sammensætninger
FI924457A0 (fi) Kompositioner och behandlingsfoerfarande foer lunginflammation i djur
DK0563254T3 (da) Anvendelse af IL-4 til forstærkning af immunrespons på immunogener i vacciner
DE69420970D1 (de) Impfstoff zubereitungen
NO175846C (no) Fremgangsmåte for å oppnå et immunogen
DE69322960D1 (de) Empfängnisverhütender impfstoff

Legal Events

Date Code Title Description
FD Application lapsed